Page 8 - Management of Advanced Urothelial Carcinoma: Emerging Therapies and Biomarkers
P. 8
The Treatment Landscape for mUC is Evolving
2016 2016- 2018
2017 +
4 Checkpoint Newly approved and
Chemotherapy Inhibitors Approved emerging therapies
for UC *
< 2016, no major improvements in Use of checkpoint inhibitors Management algorithm
therapeutic efficacy for constitutes most incorporates new treatments and
metastatic UC seen in the past substantial change in management required
30+ years for biomarker testing
bladder cancer
*Some checkpoint inhibitors are approved as line 1 therapy for cisplatin-ineligible patients; all are approved as 2 nd line therapy.
mUC, metastatic urothelial cancer.
https://www.urotoday.com/journal/everyday-urology-oncology-insights/articles/93131-systemic-immunotherapy-bladder-cancer-get-ready-everyday-urology-full-text-
article.html. Accessed October 30, 2018; Cheetham PJ and Petrylak DP. Oncology. 2016;30(6):571–9,588.
